FAQ: Phlow Corp's $37 Million Series C Funding Round and Its Impact on Pharmaceutical Manufacturing
Summary
Phlow Corp, a Richmond, Va.-based CDMO, has secured a $37 million Series C funding round led by Align Private Capital, marking a significant step towards enhancing the U.S. pharmaceutical supply chain and addressing drug shortages.
What is Phlow Corp?
Phlow Corp is a Richmond, Va.-based contract development and manufacturing organization (CDMO) focused on producing medicine critical to the nation’s healthcare.
Who led the Series C funding round for Phlow Corp?
The $37 million Series C funding round was led by Align Private Capital, a woman-owned firm based in Florida.
How much has Phlow Corp raised in total?
Phlow Corp has raised over $93 million in private capital, alongside more than $600 million in awarded government contracts.
What are the key milestones Phlow Corp has achieved this year?
Key milestones include the opening of two newly operational U.S.-based cGMP manufacturing facilities and a partnership with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
What is the significance of Phlow Corp’s funding?
The funding validates Phlow’s mission to stabilize the U.S. pharmaceutical supply chain and end chronic shortages of essential medicines, accelerating their API development and manufacturing programs.
Who is Eric S. Edwards?
Eric S. Edwards is the Chairman and CEO of Phlow Corp, a co-founder of Kaleo, and holds multiple degrees in Biology, Pharmaceutical Sciences, and Medicine from Virginia Commonwealth University.
What is the Children’s Hospital Coalition?
The Children’s Hospital Coalition is Phlow Corp’s initiative to combat pediatric drug shortages, under which it has shipped over 1.6 million vials of essential medicines to children’s hospitals across the country.
How does Phlow Corp contribute to the U.S. military?
Phlow Corp partners with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop medical countermeasure drugs for the U.S. military and its allies.
What does Anna Nekoranec say about Phlow Corp?
Anna Nekoranec, CEO of Align Private Capital, supports Phlow’s initiatives to address inefficiencies in the U.S. pharmaceutical supply chain, especially in preventing pediatric drug shortages and supporting the U.S. military.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at citybiz
Article Control ID: 121677